Hopes for Brexucabtagene Autoleucel in Mantle Cell Lymphoma
Lori Leslie, MD, describes the cohorts of the phase 2 ZUMA-2 study and discusses the potential impact of brexucabtagene autoleucel in the mantle cell lymphoma landscape.
Acalabrutinib May Be an Alternative to Ibrutinib For Treatment of CLL
Lori Leslie, MD, discusses toxicities and outcomes observed in patients with chronic lymphocytic leukemia treated with acalabrutinib in real-word clinics.